Fruquintinib

DB11679ApprovedInvestigationalSmall molecule

Fruquintinib is a VEGF receptor inhibitor used to treat metastatic colorectal cancer. Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis.

Chemical structure of Fruquintinib
Mechanism
Curator reviewed
Primary indication
Fruquintinib is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate,...Curator reviewed · 4 structured indications
Formula / weight
C21H19N3O5 · 393.399 g/mol (avg)
First approval
Canada, 2024 · United States, 2023 · European Union, 2025
Code names
HMPL-013
Brand names
  • Fruzaqla

Resolves to

Compound
UNII49DXG3M5ZWCAS1194506-26-7ChEMBLCHEMBL4303214ChEBI229221PubChem44480399
Clinical / RWD
RxNorm2670179ATCL01EK04
Structure
InChIKeyBALLNEJQLSTPIO-UHFFFAOYSA-NSMILESCNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12
Targets
P17948FLT1P35968KDRP35916FLT4

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
684Drug interactionsStructured to mechanism, not free text
Sign in
161Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
6Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fruquintinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In